Discover.
Launch.
Build.
Transform.

Living our core values.

One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.

Learn More

Faze Medicines

Faze is leveraging the groundbreaking new science of biomolecular condensates to develop therapies to slow, halt, or reverse disease pathology.

Faze Medicines

MOMA Therapeutics

The current era of disease genetics and whole genome profiling have defined molecular machines as the best intervention points in numerous diseases. MOMA's mission is to discover the next generation of precision medicines by targeting the molecular machines that underlie diseases.

MOMA Therapeutics

Blueprint Medicines

Blueprint received approval from the U.S. Food and Drug Administration (FDA) for GAVRETO™ (pralsetinib) for the treatment of adult patients with RET fusion-positive non-small cell lung cancer and thyroid cancer. This approval brings forward a new standard of care for a genomically defined population of patients that previously had very limited treatment options.

Blueprint Medicines

GBT

GBT received accelerated approval from the U.S. Food and Drug Administration (FDA) for Oxbryta™ (voxelotor) for the treatment of sickle cell disease (SCD). The once-daily pill is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

GBT
13

Years

55

Portfolio Companies

15

Marketed Products

1

Priority: Patients